<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7138156\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="her treatment plan. Maria was a 26-year-old woman with relapsing" exact="multiple sclerosis" post="who had recently experienced brainstem relapse with double vision"/>
  <result pre="who had recently experienced brainstem relapse with double vision and" exact="ataxia" post="despite treatment with pegylated interferon-beta for the last 18"/>
  <result pre="treatment with pegylated interferon-beta for the last 18 months. A" exact="brain" post="MRI performed one month prior had shown 16 new"/>
  <result pre="what should neurologists do? Human coronaviruses are predominantly associated with" exact="respiratory" post="tract infections and includes those that cause severe acute"/>
  <result pre="neurologists do? Human coronaviruses are predominantly associated with respiratory tract" exact="infections" post="and includes those that cause severe acute respiratory syndrome"/>
  <result pre="with respiratory tract infections and includes those that cause severe" exact="acute" post="respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and"/>
  <result pre="respiratory tract infections and includes those that cause severe acute" exact="respiratory" post="syndrome (SARS), Middle East respiratory syndrome (MERS) and now"/>
  <result pre="tract infections and includes those that cause severe acute respiratory" exact="syndrome" post="(SARS), Middle East respiratory syndrome (MERS) and now the"/>
  <result pre="those that cause severe acute respiratory syndrome (SARS), Middle East" exact="respiratory" post="syndrome (MERS) and now the COVID-19 pandemic. In an"/>
  <result pre="that cause severe acute respiratory syndrome (SARS), Middle East respiratory" exact="syndrome" post="(MERS) and now the COVID-19 pandemic. In an uncertain"/>
  <result pre="but do not address supervision of these patients in the" exact="intermediate" post="or long-term especially those with highly active MS. If"/>
  <result pre="epidemic, but extend its tail, the problem of community-acquired SARS-CoV2" exact="infection" post="and COVID-19 may be with us for many months"/>
  <result pre="elderly and people with comorbidities such as hypertension, smoking and" exact="lung disease." post="At present we do not know if people with"/>
  <result pre="the brains and spinal cords of our patients with active" exact="multiple sclerosis?" post="We could argue that solid-organ transplant patients are significantly"/>
  <result pre="solid-organ transplant patients are significantly more immunocompromised than pwMS on" exact="disease" post="modifying treatment (DMT). Most transplant patients are on triple"/>
  <result pre="may prevent severe complications associated with COVID-19 infection. The severe" exact="pulmonary" post="complications of COVID-19 infection are consistent with ARDS (acute"/>
  <result pre="associated with COVID-19 infection. The severe pulmonary complications of COVID-19" exact="infection" post="are consistent with ARDS (acute respiratory distress syndrome) caused"/>
  <result pre="pulmonary complications of COVID-19 infection are consistent with ARDS (acute" exact="respiratory" post="distress syndrome) caused by an over-exuberant immune response to"/>
  <result pre="likely to mutate rapidly making a one-off vaccine only a" exact="partial" post="solution. Vaccines take time to be developed, tested and"/>
  <result pre="of the factors. Other aspects to consider, when assessing a" exact="respiratory" post="viral infection include: smoking practices (increased cigarette smoking increases"/>
  <result pre="the factors. Other aspects to consider, when assessing a respiratory" exact="viral infection" post="include: smoking practices (increased cigarette smoking increases risk); ambulatory"/>
  <result pre="factors. Other aspects to consider, when assessing a respiratory viral" exact="infection" post="include: smoking practices (increased cigarette smoking increases risk); ambulatory"/>
  <result pre="age increases risk); weight (increasing weight impacts on ambulation and" exact="respiratory" post="function); underlying respiratory illnesses, such as asthma or COPD."/>
  <result pre="weight (increasing weight impacts on ambulation and respiratory function); underlying" exact="respiratory" post="illnesses, such as asthma or COPD. Also, the frequency"/>
  <result pre="on ambulation and respiratory function); underlying respiratory illnesses, such as" exact="asthma" post="or COPD. Also, the frequency of necessary attendance at"/>
  <result pre="paients who don't develop a persistent lymphopaenia. Patients with a" exact="total" post="lymphocyte count of less than 800/mm3 should be considered"/>
  <result pre="in mucosal surfaces and the gut that may promote prolonged" exact="viral" post="shedding. Also risk that as COVID-19/SARS-CoV-2 is neurotropic it"/>
  <result pre="Also risk that as COVID-19/SARS-CoV-2 is neurotropic it may prevent" exact="viral" post="clearance from the CNS. Intermediate S1P modulators Fingolimod (Gilenya),"/>
  <result pre="CNS. Intermediate S1P modulators Fingolimod (Gilenya), Siponimod (Mazent), Ozanimod, Ponesimod" exact="Selective" post="S1P modulator, prevents egress of lymphocytes from lymph nodes"/>
  <result pre="continous Theoretical risk that S1P modulators may result in prolonged" exact="viral" post="shedding. Paradoxically S1P modulators may reduce the severity of"/>
  <result pre="that ocrelizumab and other anti-CD20 therapies may result in prolonged" exact="viral" post="shedding. Intermediate Cladribine Mavenclad Deoxyadenosine (purine) analogue, adenosine deaminase"/>
  <result pre="in the immune depletion phase cladribine may result in prolonged" exact="viral" post="shedding. High* Mitoxantrone Novatrone Immune depleter (topoisomerase inhibitor) Very"/>
  <result pre="in the immune depletion phase mitoxantrone may result in prolonged" exact="viral" post="shedding. High* Alemtuzumab Lemtrada Anti-CD52, non-selective immune depleter Very"/>
  <result pre="in the immune depletion phase alemtuzumab may result in prolonged" exact="viral" post="shedding. High* HSCT - Immune depletion and haemopoietic stem"/>
  <result pre="in the immune depletion phase HSCT may result in prolonged" exact="viral" post="shedding. â�Žrisk refers to acquiring an infection during the"/>
  <result pre="result in prolonged viral shedding. â�Žrisk refers to acquiring an" exact="infection" post="during the immunodepletion phase. Post immune reconstitution the risk"/>
  <result pre="mitoxantrone (Novantrone) and cladribine (Mavenclad). After immune reconstitution, once the" exact="total" post="lymphocyte counts have returned to normal or near normal"/>
  <result pre="returned to normal or near normal the risk of severe" exact="viral" post="infections are probably no higher than expected for the"/>
  <result pre="to normal or near normal the risk of severe viral" exact="infections" post="are probably no higher than expected for the background"/>
  <result pre="the previous 6â€&quot;12 months they may still be immunocompromised. A" exact="total" post="lymphocyte count less 1.1Â Ã—Â 109/L or 1100/mm3 is"/>
  <result pre="109/L or 1100/mm3 is associated with an increased risk of" exact="infection" post="and infection-related mortality (WarnyÂ etÂ al., 2018). This risk"/>
  <result pre="mortality (WarnyÂ etÂ al., 2018). This risk increases progressively the" exact="lower" post="the absolute lymphocyte counts; particularly when the lymphocyte count"/>
  <result pre="above 800/mm3 (WHO grade 2) are able to deal with" exact="viral" post="infections reasonably well provided they have no other comorbidities"/>
  <result pre="800/mm3 (WHO grade 2) are able to deal with viral" exact="infections" post="reasonably well provided they have no other comorbidities and"/>
  <result pre="Of the immune reconstitution therapies, cladribine (Mavenclad) is classed as" exact="intermediate" post="risk, because it is a relatively poor T-cell depleting"/>
  <result pre="than the CD8+ population. In the phase 3 CLARITY study," exact="viral" post="infections were uncommon post-cladribine and apart from herpes zoster,"/>
  <result pre="the CD8+ population. In the phase 3 CLARITY study, viral" exact="infections" post="were uncommon post-cladribine and apart from herpes zoster, infections"/>
  <result pre="CLARITY study, viral infections were uncommon post-cladribine and apart from" exact="herpes zoster," post="infections were no more frequent in cladribine-treated subjects compared"/>
  <result pre="viral infections were uncommon post-cladribine and apart from herpes zoster," exact="infections" post="were no more frequent in cladribine-treated subjects compared to"/>
  <result pre="cladribine-treated subjects compared to placebo (CookÂ etÂ al., 2011). When" exact="viral" post="infections occurred post-cladribine they tended to be mild or"/>
  <result pre="subjects compared to placebo (CookÂ etÂ al., 2011). When viral" exact="infections" post="occurred post-cladribine they tended to be mild or moderate"/>
  <result pre="impact on T-cell counts and are not associated with severe" exact="viral" post="infections (MayerÂ etÂ al., 2019). In the phase 3"/>
  <result pre="on T-cell counts and are not associated with severe viral" exact="infections" post="(MayerÂ etÂ al., 2019). In the phase 3 relapsing-remitting"/>
  <result pre="(MayerÂ etÂ al., 2019). In the phase 3 relapsing-remitting and" exact="primary" post="progressive trials, infections were slightly more frequent on ocrelizumab"/>
  <result pre="2019). In the phase 3 relapsing-remitting and primary progressive trials," exact="infections" post="were slightly more frequent on ocrelizumab compared to comparator"/>
  <result pre="etÂ al., 2017; MontalbanÂ etÂ al., 2017). Most of these" exact="infections" post="were mild and moderate with the severe infections being"/>
  <result pre="of these infections were mild and moderate with the severe" exact="infections" post="being bacterial in nature (pneumonia, urinary tract infections and"/>
  <result pre="infections were mild and moderate with the severe infections being" exact="bacterial" post="in nature (pneumonia, urinary tract infections and cellulitis). We"/>
  <result pre="moderate with the severe infections being bacterial in nature (pneumonia," exact="urinary tract infections" post="and cellulitis). We therefore feel that both cladribine and"/>
  <result pre="the severe infections being bacterial in nature (pneumonia, urinary tract" exact="infections" post="and cellulitis). We therefore feel that both cladribine and"/>
  <result pre="ozanimod, ponesimod) work by reducing the egress of lymphocytes from" exact="secondary" post="lymphoid organs into the circulation (StepanovskaÂ and Huwiler,Â 2019)."/>
  <result pre="is not associated with their efficacy nor the risk of" exact="infection" post="(FrancisÂ etÂ al., 2014). Overall infectious complications are relatively"/>
  <result pre="nor the risk of infection (FrancisÂ etÂ al., 2014). Overall" exact="infectious" post="complications are relatively low on S1P modulators, with opportunistic"/>
  <result pre="Overall infectious complications are relatively low on S1P modulators, with" exact="opportunistic infections" post="emerging over time (EpsteinÂ etÂ al., 2018; LunaÂ etÂ"/>
  <result pre="infectious complications are relatively low on S1P modulators, with opportunistic" exact="infections" post="emerging over time (EpsteinÂ etÂ al., 2018; LunaÂ etÂ"/>
  <result pre="S1P modulators do not have a problem dealing with community" exact="acquired" post="viral infections. Patients on fingolimod who are exposed to"/>
  <result pre="modulators do not have a problem dealing with community acquired" exact="viral" post="infections. Patients on fingolimod who are exposed to and"/>
  <result pre="Patients on fingolimod who are exposed to and acquire exotic" exact="viral" post="infections such as dengue fever seem to deal with"/>
  <result pre="on fingolimod who are exposed to and acquire exotic viral" exact="infections" post="such as dengue fever seem to deal with them"/>
  <result pre="are exposed to and acquire exotic viral infections such as" exact="dengue fever" post="seem to deal with them without complications (FragosoÂ etÂ"/>
  <result pre="should be at relatively low risk of complications from COVID-19" exact="infection" post="and why it may be safe to continue these"/>
  <result pre="natalizumab relatively safe there is a small increased risk of" exact="upper" post="respiratory tract infections on this medication (KapoorÂ etÂ al.,"/>
  <result pre="relatively safe there is a small increased risk of upper" exact="respiratory" post="tract infections on this medication (KapoorÂ etÂ al., 2018;"/>
  <result pre="there is a small increased risk of upper respiratory tract" exact="infections" post="on this medication (KapoorÂ etÂ al., 2018; PolmanÂ etÂ"/>
  <result pre="it may reduce trafficking of lymphocytes in the lung and" exact="mucosa" post="(WoodsideÂ and Vanderslice,Â 2008). It is clear that natalizumab"/>
  <result pre="CNS, hence a person on natalizumab who develops a COVID-19" exact="encephalitis" post="could be in danger of major complications of this"/>
  <result pre="The latter is analogous to PML, which is also a" exact="viral encephalitis," post="and similar to herpes-simplex and varicella -zoster encephalitis resulting"/>
  <result pre="a viral encephalitis, and similar to herpes-simplex and varicella -zoster" exact="encephalitis" post="resulting from natalizumab exposure (FineÂ etÂ al., 2013). Coronaviruses"/>
  <result pre="of consciousness with a normal CT scan of the brain." exact="Spinal" post="fluid analysis revealed SARS-CoV-2. He subsequently made a recovery"/>
  <result pre="Another human coronavirus HCoV-OC43, which is generally associated with mild" exact="upper" post="respiratory tract infections, has been shown to have neuroinvasive"/>
  <result pre="human coronavirus HCoV-OC43, which is generally associated with mild upper" exact="respiratory" post="tract infections, has been shown to have neuroinvasive properties."/>
  <result pre="mice have shown that HCoV-OC43 can infect neurons and cause" exact="encephalitis" post="and cause persistent infections in human neural-cell lines (ArbourÂ"/>
  <result pre="HCoV-OC43 can infect neurons and cause encephalitis and cause persistent" exact="infections" post="in human neural-cell lines (ArbourÂ etÂ al., 1999). There"/>
  <result pre="case reports identifying HCoV-OC43 RNA in the cerebrospinal fluid or" exact="brain" post="of children with acute disseminated encephalomyelitis (YehÂ etÂ al.,"/>
  <result pre="RNA in the cerebrospinal fluid or brain of children with" exact="acute" post="disseminated encephalomyelitis (YehÂ etÂ al., 2004) and acute encephalomyelitis"/>
  <result pre="the cerebrospinal fluid or brain of children with acute disseminated" exact="encephalomyelitis" post="(YehÂ etÂ al., 2004) and acute encephalomyelitis (MorfopoulouÂ etÂ"/>
  <result pre="children with acute disseminated encephalomyelitis (YehÂ etÂ al., 2004) and" exact="acute" post="encephalomyelitis (MorfopoulouÂ etÂ al., 2016). Coronaviruses mutate very rapidly"/>
  <result pre="with acute disseminated encephalomyelitis (YehÂ etÂ al., 2004) and acute" exact="encephalomyelitis" post="(MorfopoulouÂ etÂ al., 2016). Coronaviruses mutate very rapidly and"/>
  <result pre="trafficking to the gut and is a licensed treatment for" exact="Crohn's disease" post="(GhoshÂ etÂ al., 2003). Will patients on natalizumab and"/>
  <result pre="to the gut and is a licensed treatment for Crohn's" exact="disease" post="(GhoshÂ etÂ al., 2003). Will patients on natalizumab and"/>
  <result pre="2003). Will patients on natalizumab and other DMTs have increased" exact="viral" post="replication in the gut and shedding in the stool?"/>
  <result pre="on natalizumab should be able to deal with a novel" exact="viral infection" post="such as dengue (FragosoÂ etÂ al., 2016b). Reassuringly, five"/>
  <result pre="natalizumab should be able to deal with a novel viral" exact="infection" post="such as dengue (FragosoÂ etÂ al., 2016b). Reassuringly, five"/>
  <result pre="considered carefully. The COVID-19 pandemic in all likelihood will be" exact="short" post="lived and it would be unfair to patients treated"/>
  <result pre="to treat MS proactively to a target of no evident" exact="disease" post="activity (NEDA) and more recently, to flip the pyramid"/>
  <result pre="the COVID-19 epidemics These are recommendations made by neurologists and" exact="infectious diseases" post="specialists whilst we have no evidence-based data at present."/>
  <result pre="Given the lack of knowledge or data on the COVID-19" exact="disease" post="course in MS patients receiving DMTs, at present there"/>
  <result pre="decision should be made according to individual factors such as" exact="disease" post="severity and activity. For anti-CD2O DMTs it is recommended"/>
  <result pre="cycle, it is recommended to give the second dose (i.e." exact="complete" post="the first cycle) and â€˜extra precautionsâ€™ should be taken."/>
  <result pre="until clinical resolution and/or approval to continue treatment by an" exact="infectious disease" post="specialist. Note: given the potential antiviral activity of beta-interferons,"/>
  <result pre="clinical resolution and/or approval to continue treatment by an infectious" exact="disease" post="specialist. Note: given the potential antiviral activity of beta-interferons,"/>
  <result pre="AndersenK.G.RambautA.Ian LipkinW.HolmesE.C.GarryR.F.The proximal origin of SARS-CoV-2Nat. Med.202010.1038/s41591-020-0820-9https://doi.org/ ArbourN.CÃ´tÃ©G.LachanceC.TardieuM.CashmanN.R.TalbotP.J.Acute and persistent" exact="infection" post="of human neural cell lines by human coronavirus OC43J."/>
  <result pre="cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating" exact="multiple sclerosis" post="orallY) studyMult. Scler.17201157859321228029 EpsteinD.J.DunnJ.DeresinskiS.Infectious complications of multiple sclerosis therapies:"/>
  <result pre="Tablets treating multiple sclerosis orallY) studyMult. Scler.17201157859321228029 EpsteinD.J.DunnJ.DeresinskiS.Infectious complications of" exact="multiple sclerosis" post="therapies: implications for screening, prophylaxis, and managementOpen Forum Infect."/>
  <result pre="screening, prophylaxis, and managementOpen Forum Infect. Dis.52018ofy17430094293 FineA.J.SorbelloA.KortepeterC.ScarazziniL.Central nervous system" exact="herpes" post="simplex and varicella zoster virus infections in natalizumab-treated patientsClin."/>
  <result pre="Forum Infect. Dis.52018ofy17430094293 FineA.J.SorbelloA.KortepeterC.ScarazziniL.Central nervous system herpes simplex and varicella" exact="zoster" post="virus infections in natalizumab-treated patientsClin. Infect. Dis.57201384985223728144 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue"/>
  <result pre="Dis.52018ofy17430094293 FineA.J.SorbelloA.KortepeterC.ScarazziniL.Central nervous system herpes simplex and varicella zoster virus" exact="infections" post="in natalizumab-treated patientsClin. Infect. Dis.57201384985223728144 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in"/>
  <result pre="natalizumab-treated patientsClin. Infect. Dis.57201384985223728144 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in patients with" exact="multiple sclerosis" post="taking fingolimod or natalizumabMult. Scler. Relat. Disord.62016646527063625 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue"/>
  <result pre="natalizumabMult. Scler. Relat. Disord.62016646527063625 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in patients with" exact="multiple sclerosis" post="taking fingolimod or natalizumabMult. Scler. Relat. Disord.62016646527063625 FrancisG.KapposL.O'ConnorP.CollinsW.TangD.MercierF.CohenJ.A.Temporal profile"/>
  <result pre="Relat. Disord.62016646527063625 FrancisG.KapposL.O'ConnorP.CollinsW.TangD.MercierF.CohenJ.A.Temporal profile of lymphocyte counts and relationship with" exact="infections" post="with fingolimod therapyMult. Scler.20201447148023950550 GhoshS.GoldinE.GordonF.H.MalchowH.A.Rask-MadsenJ.RutgeertsP.VyhnÃ¡lekP.ZÃ¡dorovÃ¡Z.PalmerT.DonoghueS.collab: Natalizumab Pan-European Study GroupNatalizumab"/>
  <result pre="China Medical Treatment Expert Group for Covid-19Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN. Engl. J. Med.202010.1056/NEJMoa2002032https://doi.org/ HauserS.L.Bar-OrA.ComiG.GiovannoniG.HartungH.-P.HemmerB.LublinF.MontalbanX.RammohanK.W.SelmajK.TraboulseeA.WolinskyJ.S.ArnoldD.L.KlingelschmittG.MastermanD.FontouraP.BelachewS.ChinP.MaironN.GarrenH.KapposL.OPERAIcollab: OPERA II"/>
  <result pre="StatesN. Engl. J. Med.382202092993632004427 KapoorR.HoP.-R.CampbellN.ChangI.DeykinA.ForrestalF.LucasN.YuB.ArnoldD.L.FreedmanM.S.GoldmanM.D.HartungH.-P.HavrdovÃ¡E.K.JefferyD.MillerA.SellebjergF.CadavidD.MikolD.SteinerD.collab: ASCEND investigatorsEffect of natalizumab on" exact="disease" post="progression in secondary progressive multiple sclerosis (ASCEND): a phase"/>
  <result pre="Med.382202092993632004427 KapoorR.HoP.-R.CampbellN.ChangI.DeykinA.ForrestalF.LucasN.YuB.ArnoldD.L.FreedmanM.S.GoldmanM.D.HartungH.-P.HavrdovÃ¡E.K.JefferyD.MillerA.SellebjergF.CadavidD.MikolD.SteinerD.collab: ASCEND investigatorsEffect of natalizumab on disease progression in" exact="secondary" post="progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind,"/>
  <result pre="ASCEND investigatorsEffect of natalizumab on disease progression in secondary progressive" exact="multiple sclerosis" post="(ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with"/>
  <result pre="fingolimod-treated patients with multiple sclerosisNeurology84201587287925636714 LunaG.AlpingP.BurmanJ.FinkK.Fogdell-HahnA.GunnarssonM.HillertJ.Langer-GouldA.LyckeJ.NilssonP.SalzerJ.SvenningssonA.VrethemM.OlssonT.PiehlF.FrisellT.Infection risks among patients with" exact="multiple sclerosis" post="treated with fingolimod, natalizumab, rituximab, and injectable therapiesJAMA Neurol.201910.1001/jamaneurol.2019.3365https://doi.org/"/>
  <result pre="therapiesJAMA Neurol.201910.1001/jamaneurol.2019.3365https://doi.org/ MayerL.KapposL.RackeM.K.RammohanK.TraboulseeA.HauserS.L.JulianL.KÃ¶ndgenH.LiC.NapieralskiJ.ZhengH.WolinskyJ.S.Ocrelizumab infusion experience in patients with relapsing and" exact="primary" post="progressive multiple sclerosis: Results from the phase 3 randomized"/>
  <result pre="Relat. Disord.30201923624330844611 MontalbanX.HauserS.L.KapposL.ArnoldD.L.Bar-OrA.ComiG.de SezeJ.GiovannoniG.HartungH.-P.HemmerB.LublinF.RammohanK.W.SelmajK.TraboulseeA.SauterA.MastermanD.FontouraP.BelachewS.GarrenH.MaironN.ChinP.WolinskyJ.S.collab: ORATORIO Clinical InvestigatorsOcrelizumab versus Placebo in" exact="primary" post="progressive multiple sclerosisN. Engl. J. Med.376201720922028002688 MorfopoulouS.BrownJ.R.DaviesE.G.AndersonG.VirasamiA.QasimW.ChongW.K.HubankM.PlagnolV.DesforgesM.JacquesT.S.TalbotP.J.BreuerJ.Human coronavirus OC43"/>
  <result pre="ARDS during the COVID-19 pandemic and other outbreaks of emerging" exact="infectious" post="diseasesLancet Respir. Med.202010.1016/s2213-2600(20)30121-1https://doi.org/ RudickR.A.StuartW.H.CalabresiP.A.ConfavreuxC.GalettaS.L.RadueE.-W.LublinF.D.Weinstock-GuttmanB.WynnD.R.LynnF.PanzaraM.A.SandrockA.W.collab: SENTINEL InvestigatorsNatalizumab plus interferon beta-1a"/>
  <result pre="receptor signaling pathways as a promising approach for treatment of" exact="autoimmune" post="and inflammatory diseasesPharmacol. Res.2019104170 StuveO.Soelberg SoerensenP.LeistT.GiovannoniG.HyvertY.DamianD.DangondF.BoschertU.Effects of cladribine tablets"/>
  <result pre="of surface markersTher. Adv. Neurol. Disord.1220191756286419854986 WarnyM.HelbyJ.NordestgaardB.G.BirgensH.BojesenS.E.Lymphopenia and risk of" exact="infection" post="and infection-related death in 98,344 individuals from a prospective"/>
  <result pre="Danish population-based studyPLoS Med.152018e1002685 WoodsideD.G.VandersliceP.Cell adhesion antagonists: therapeutic potential in" exact="asthma" post="and chronic obstructive pulmonary diseaseBioDrugs2220088510018345706 XinhuaBeijing hospital confirms nervous"/>
  <result pre="studyPLoS Med.152018e1002685 WoodsideD.G.VandersliceP.Cell adhesion antagonists: therapeutic potential in asthma and" exact="chronic" post="obstructive pulmonary diseaseBioDrugs2220088510018345706 XinhuaBeijing hospital confirms nervous system infections"/>
  <result pre="WoodsideD.G.VandersliceP.Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive" exact="pulmonary" post="diseaseBioDrugs2220088510018345706 XinhuaBeijing hospital confirms nervous system infections by novel"/>
  <result pre="and chronic obstructive pulmonary diseaseBioDrugs2220088510018345706 XinhuaBeijing hospital confirms nervous system" exact="infections" post="by novel coronavirus [WWW Document]XinhuaNet2020URLhttp://www.xinhuanet.com/english/2020-03/05/c_138846529.htm(accessed 11.3.20) YehE.A.CollinsA.CohenM.E.DuffnerP.K.FadenH.Detection of coronavirus"/>
  <result pre="novel coronavirus [WWW Document]XinhuaNet2020URLhttp://www.xinhuanet.com/english/2020-03/05/c_138846529.htm(accessed 11.3.20) YehE.A.CollinsA.CohenM.E.DuffnerP.K.FadenH.Detection of coronavirus in the" exact="central nervous system" post="of a child with acute disseminated encephalomyelitisPediatrics1132004e73e7614702500"/>
  <result pre="coronavirus in the central nervous system of a child with" exact="acute" post="disseminated encephalomyelitisPediatrics1132004e73e7614702500"/>
 </snippets>
</snippetsTree>
